Association of promoter variants of human dopamine transporter gene with schizophrenia in Han Chinese

Schizophrenia Research

Volumn 116, Issue 1, 2010, Pages 68-74

  Huang, San Yuan ^a   Chen, Hsing Kang ^a,e   Ma, Kuo Hsing ^b   Shy, Mee Jen ^a,b   Chen, Jiun Hsiung ^a,d   Lin, Wen chi ^a   Lu, Ru Band ^a,c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c Institute of Molecular and Cellular Biology   (Taiwan)

^d Gangshan Armed Forces Hospital   (Taiwan)

^e Yuli Hospital Department of Health Taiwan   (Taiwan)

Author keywords

Age of onset; Dopamine transporter gene; Promoter variants; Psychotic symptoms; Schizophrenia

Indexed keywords

DOPAMINE TRANSPORTER;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; ANALYSIS OF VARIANCE; ASIAN CONTINENTAL ANCESTRY GROUP; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 71649102773     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.10.004     Document Type: Article

References (33)

1. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265 Oxford, England
2. Birkett P., Sigmundsson T., Sharma T., Toulopoulou T., Griffiths T.D., Reveley A., and Murray R. Executive function and genetic predisposition to schizophrenia-the Maudsley family study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147 (2008) 285-293
3. Borowski T.B., and Kokkinidis L. The effects of cocaine, amphetamine, and the dopamine D1 receptor agonist SKF 38393 on fear extinction as measured with potentiated startle: implications for psychomotor stimulant psychosis. Behav. Neurosci. 112 (1998) 952-965
4. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 2569-2574
5. Buchner A., Faul F., and Erdfelder E. G-power: A Priori, Post Hoc, and Compromise Power Analyses for the Macintosh, Version 2.1.1 (1996), University of Trier, Trier, Germany
6. Cardno A.G., Thomas K., and McGuffin P. Clinical variables and genetic loading for schizophrenia: analysis of published Danish adoption study data. Schizophr. Bull. 28 (2002) 393-399
7. Carvelli L., Blakely R.D., and DeFelice L.J. Dopamine transporter/syntaxin 1A interactions regulate transporter channel activity and dopaminergic synaptic transmission. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 14,192-14,197
8. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
9. Endicott J., and Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry 35 (1978) 837-844
10. Fanous A.H., and Kendler K.S. Genetic heterogeneity, modifier genes, and quantitative phenotypes in psychiatric illness: searching for a framework. Mol. Psychiatry 10 (2005) 6-13
11. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Lochner A., Faggart M., Liu-Cordero S.N., Rotimi C., Adeyemo A., Cooper R., Ward R., Lander E.S., Daly M.J., and Altshuler D. The structure of haplotype blocks in the human genome. Science 296 (2002) 2225-2229 New York, NY
12. Gamma F., Faraone S.V., Glatt S.J., Yeh Y.C., and Tsuang M.T. Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene. Schizophr. Res. 73 (2005) 55-58
13. Genro J.P., Zeni C., Polanczyk G.V., Roman T., Rohde L.A., and Hutz M.H. A promoter polymorphism (- 839 C > T) at the dopamine transporter gene is associated with attention deficit/hyperactivity disorder in Brazilian children. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144 (2007) 215-219
14. Giros B., and Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14 (1993) 43-49
15. Goldstein M., and Deutch A.Y. Dopaminergic mechanisms in the pathogenesis of schizophrenia. Faseb J. 6 (1992) 2413-2421
16. Greenwood T.A., and Kelsoe J.R. Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82 (2003) 511-520
17. Haeffel G.J., Getchell M., Koposov R.A., Yrigollen C.M., Deyoung C.G., Klinteberg B.A., Oreland L., Ruchkin V.V., and Grigorenko E.L. Association between polymorphisms in the dopamine transporter gene and depression: evidence for a gene-environment interaction in a sample of juvenile detainees. Psychol. Sci. 19 (2008) 62-69
18. Hjerde E., Dahl S.G., and Sylte I. Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. Eur. J. Med. Chem. 40 (2005) 185-194
19. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., Bramon-Bosch E., Valmaggia L., Johns L., Broome M., McGuire P.K., and Grasby P.M. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 66 (2009) 13-20
20. Huang S.Y., Lin W.W., Ko H.C., Lee J.F., Wang T.J., Chou Y.H., Yin S.J., and Lu R.B. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin. Exp. Res. 28 (2004) 374-384
21. Huang S.Y., Lin W.W., Wan F.J., Chang A.J., Ko H.C., Wang T.J., Wu P.L., and Lu R.B. Monoamine oxidase-A polymorphisms might modify the association between the dopamine D2 receptor gene and alcohol dependence. J. Psychiatry Neurosci. 32 (2007) 185-192
22. Kay S.R., F.A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
23. Keikhaee M.R., Fadai F., Sargolzaee M.R., Javanbakht A., Najmabadi H., and Ohadi M. Association analysis of the dopamine transporter (DAT1)-67A/T polymorphism in bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 135 (2005) 47-49
24. Khodayari N., Garshasbi M., Fadai F., Rahimi A., Hafizi L., Ebrahimi A., Najmabadi H., and Ohadi M. Association of the dopamine transporter gene (DAT1) core promoter polymorphism -67T variant with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129 (2004) 10-12
25. Merikangas K.R., Stevens D.E., Fenton B., Stolar M., O'Malley S., Woods S.W., and Risch N. Co-morbidity and familial aggregation of alcoholism and anxiety disorders. Psychol. Med. 28 (1998) 773-788
26. Noble E.P. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 116B (2003) 103-125
27. Pompanon F., Bonin A., Bellemain E., and Taberlet P. Genotyping errors: causes, consequences and solutions. Nat. Rev. 6 (2005) 847-859
28. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am. J. Hum. Genet. 46 (1990) 222-228
29. Rubie C., Schmidt F., Knapp M., Sprandel J., Wiegand C., Meyer J., Jungkunz G., Riederer P., and Stober G. The human dopamine transporter gene: the 5′-flanking region reveals five diallelic polymorphic sites in a Caucasian population sample. Neurosci. Lett. 297 (2001) 125-128
30. Stober G., Sprandel J., Jabs B., Pfuhlmann B., Moller-Ehrlich K., and Knapp M. Family-based study of markers at the 5′-flanking region of the human dopamine transporter gene reveals potential association with schizophrenic psychoses. Eur. Arch. Psychiatry Clin. Neurosci. 256 (2006) 422-427
31. Toulopoulou T., Picchioni M., Rijsdijk F., Hua-Hall M., Ettinger U., Sham P., and Murray R. Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch. Gen. Psychiatry 64 (2007) 1348-1355
32. van de Giessen E.M., de Win M.M., Tanck M.W., van den Brink W., Baas F., and Booij J. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J. Nucl. Med. 50 (2009) 45-52
33. Zhang A., Xing Q., Wang L., Du J., Yu L., Lin Z., Li X., Feng G., and He L. Dopamine transporter polymorphisms and risperidone response in Chinese schizophrenia patients: an association study. Pharmacogenomics 8 (2007) 1337-1345